Norway · Delayed Price · Currency is NOK General Oceans ASA Statistics
Total Valuation
OSL:GENO has a market cap or net worth of NOK 3.59 billion. The enterprise value is 2.91 billion.
| Market Cap | 3.59B |
| Enterprise Value | 2.91B |
Important Dates
The next confirmed earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OSL:GENO has 190.11 million shares outstanding. The number of shares has increased by 14.95% in one year.
| Current Share Class | 190.11M |
| Shares Outstanding | 190.11M |
| Shares Change (YoY) | +14.95% |
| Shares Change (QoQ) | -1.65% |
| Owned by Insiders (%) | 43.88% |
| Owned by Institutions (%) | 12.63% |
| Float | 52.47M |
Valuation Ratios
The trailing PE ratio is 20.01 and the forward PE ratio is 18.11.
| PE Ratio | 20.01 |
| Forward PE | 18.11 |
| PS Ratio | 2.84 |
| PB Ratio | 3.08 |
| P/TBV Ratio | 3.95 |
| P/FCF Ratio | 34.20 |
| P/OCF Ratio | 28.70 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.28, with an EV/FCF ratio of 27.74.
| EV / Earnings | 18.39 |
| EV / Sales | 2.30 |
| EV / EBITDA | 13.28 |
| EV / EBIT | 18.07 |
| EV / FCF | 27.74 |
Financial Position
The company has a current ratio of 2.29, with a Debt / Equity ratio of 0.14.
| Current Ratio | 2.29 |
| Quick Ratio | 1.88 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.74 |
| Debt / FCF | 1.55 |
| Interest Coverage | 13.53 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 27.77% |
| Return on Capital Employed (ROCE) | 12.68% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 3.39M |
| Profits Per Employee | 425,043 |
| Employee Count | 372 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, OSL:GENO has paid 23.01 million in taxes.
| Income Tax | 23.01M |
| Effective Tax Rate | 12.70% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 22.38 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 35.12 |
| Average Volume (20 Days) | 106,701 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OSL:GENO had revenue of NOK 1.26 billion and earned 158.12 million in profits. Earnings per share was 0.94.
| Revenue | 1.26B |
| Gross Profit | 827.57M |
| Operating Income | 160.98M |
| Pretax Income | 181.13M |
| Net Income | 158.12M |
| EBITDA | 202.40M |
| EBIT | 160.98M |
| Earnings Per Share (EPS) | 0.94 |
Balance Sheet
The company has 840.13 million in cash and 163.04 million in debt, with a net cash position of 677.09 million or 3.56 per share.
| Cash & Cash Equivalents | 840.13M |
| Total Debt | 163.04M |
| Net Cash | 677.09M |
| Net Cash Per Share | 3.56 |
| Equity (Book Value) | 1.17B |
| Book Value Per Share | 6.21 |
| Working Capital | 762.48M |
Cash Flow
In the last 12 months, operating cash flow was 124.95 million and capital expenditures -20.10 million, giving a free cash flow of 104.85 million.
| Operating Cash Flow | 124.95M |
| Capital Expenditures | -20.10M |
| Depreciation & Amortization | 41.43M |
| Net Borrowing | -118.50M |
| Free Cash Flow | 104.85M |
| FCF Per Share | 0.55 |
Margins
Gross margin is 65.53%, with operating and profit margins of 12.75% and 12.52%.
| Gross Margin | 65.53% |
| Operating Margin | 12.75% |
| Pretax Margin | 14.34% |
| Profit Margin | 12.52% |
| EBITDA Margin | 16.03% |
| EBIT Margin | 12.75% |
| FCF Margin | 8.30% |
Dividends & Yields
This stock pays an annual dividend of 0.12, which amounts to a dividend yield of 0.62%.
| Dividend Per Share | 0.12 |
| Dividend Yield | 0.62% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 12.43% |
| Buyback Yield | -14.95% |
| Shareholder Yield | -14.33% |
| Earnings Yield | 4.41% |
| FCF Yield | 2.92% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for OSL:GENO is 29.00, which is 53.77% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 29.00 |
| Price Target Difference | 53.77% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 12.16% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OSL:GENO has an Altman Z-Score of 5.55 and a Piotroski F-Score of 2.
| Altman Z-Score | 5.55 |
| Piotroski F-Score | 2 |